Last reviewed · How we verify
NCT03599830: COG-IMMUNO
Study of the Cognition of Patients Treated With Immunotherapy
NA trial testing Cognitive test passations in Patients With Cancer Who Start Immunotherapy in 90 participants. Completed in 31 January 2023.
31 January 2023
Quick facts
| Lead sponsor | Centre Francois Baclesse |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 90 |
| Start date | 10 July 2018 |
| Primary completion | 31 January 2023 |
| Estimated completion | 31 January 2023 |
| Sites | 4 locations across France |
Drugs / interventions tested
- Cognitive test passations
Conditions studied
- Patients With Cancer Who Start Immunotherapy — all drugs for Patients With Cancer Who Start Immunotherapy →
- All Neoplasms — all drugs for All Neoplasms →
Sponsor
Centre Francois Baclesse — full company profile →
Who can join
18 and older, any sex, with Patients With Cancer Who Start Immunotherapy or All Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigator's longitudinal pilot study aims to evaluate for the first time the impact of immunotherapy on cognition in oncology. Due to the recent nature of immunotherapy, its side effects and impact on quality of life are still poorly understood and, to date, there is no published study evaluating the impact of immunotherapy on cognition in patients treated for cancer. The study consists of the passation of 3 neuropsychological assessments over a period of 6 months in cancer patients who start immunotherapy
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Cognitive assessment in patients treated by immunotherapy: the prospective Cog-Immuno trial.
Lange M, Clarisse B, Leconte A, Dembélé KP, et al · · 2022 · cited 10× · PMID 36513991 · DOI 10.1186/s12885-022-10384-y
Verify or expand the search:
- PubMed search for NCT03599830
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Centre Francois Baclesse trials
Trials by the same sponsor.
- NCT06959810 — Impact of Adapted Aesthetic Onco in Patients With Upper Aerodigestive Tract Cancer During Their Management · NA · recruiting
- NCT06792721 — MEASUREMENT OF CIRCULATING MUTATION BURDEN · recruiting
- NCT06817161 — Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovar · Phase 3 · recruiting
- NCT06612827 — Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions · recruiting
- NCT06798922 — Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03599830 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Francois Baclesse
- Last refreshed: 9 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03599830.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing